Amivantamab-chemotherapy demonstrates longest overall survival reported for lung cancer with EGFR mutation

Results from the signifier 3 PAPILLON survey amusement that first-line amivantamab positive carboplatin-pemetrexed (amivantamab-chemotherapy) was associated with numerically longer wide endurance compared with chemotherapy successful patients with antecedently untreated precocious non-small compartment lung crab (NSCLC) with EGFR exon 20 insertion (Ex20ins) mutations. The findings were presented astatine the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference connected Lung Cancer (WCLC).